We have collected information about Biodelivery Sciences International Onsolis for you. Follow the links to find out details on Biodelivery Sciences International Onsolis.
BioDelivery Sciences (BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ® ) technology and other drug delivery technologies to develop and commercialize new applications of proven therapies ...
http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-reacquires-onsolisr-collegium
Dec 14, 2017 · RALEIGH, N.C., Dec. 14, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that it has received the required 90-day notice from Collegium Pharmaceutical, Inc. regarding termination of the license and development agreement for ONSOLIS ® (fentanyl buccal soluble film) between BDSI and Collegium. BDSI and Collegium entered …
https://bdsi.com/About-BDSI/
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive ...
http://ir.bdsi.com/news-events/news-releases
11 rows · Mar 12, 2020 · The Investor Relations website contains information about BioDelivery …
https://www.prnewswire.com/news-releases/biodelivery-sciences-and-collegium-pharmaceutical-announce-the-signing-of-a-licensing-agreement-for-onsolis-in-the-us-300267136.html
BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S. News provided by BioDelivery Sciences International, Inc.
https://www.marketscreener.com/BIODELIVERY-SCIENCES-INTE-8541/news/BioDelivery-Sciences-International-Inc-ONSOLIS-Relaunch-Postponed-Pending-Product-Modification-14209799/
About BioDelivery Sciences International BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.
https://www.prnewswire.com/news-releases/onsolis-relaunch-postponed-pending-product-modification-142297545.html
RALEIGH, N.C., March 12, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the U.S. relaunch of ONSOLIS (fentanyl buccal soluble film) is being ...
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022266s000_ChemR_P3.pdf
Controlled Substances Act for the United States. In this NDA, NDA 22-266,Biodelivery Sciences International proposes a new dosage form for fentanyl, Onsolis (fentanyl buccal soluble film), where fentanyl is delivered through the buccal mucosa. Actiq (fentanyl citrate) oral transmucose lazcnge (Cephalon's NDA 26-747)is the reference drug product
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-licenses-us-rights-onsolisr-biodelivery-sciences
May 11, 2016 · Breakthrough cancer pain product added to the portfolio. CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS ® (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in …
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022266s000PrescriberInfo.pdf
Important Prescribing Information About ONSOLIS™ (fentanyl buccal soluble film). Dear Prescriber: ... BioDelivery Sciences International, Inc. (sponsor) / MEDA Pharmaceuticals Inc. (licensee) and their agents and contractors. Patient Signature/Date Personal Representative Signature/Date .
Searching for Biodelivery Sciences International Onsolis?
You can just click the links above. The data is collected for you.
